Advanced Colorectal Carcinoma
Conditions
Keywords
Compound kushen Injection, Traditional Chinese medicine
Brief summary
To clarify the effectiveness and safety of compound kushen injection in the treatment of advanced colorectal cancer.
Detailed description
This study include a multi-center, randomized, parallel controlled clinical trial. The randomized clinical trial will enroll approximately 320 patients. Participants will be randomly divided into experimental (n=160) and control groups (n=160). Patients in the experimental group was treated with first-line scheme + compound kushen injection. Patients in the control group will receive first-line scheme. The primary endpoint is PFS. The research protocol was approved by the relevant ethics committees, and the study was conducted according to the Declaration of Helsinki and Good Clinical Practice guidelines. Patients gave written informed consent to participate in the trial.
Interventions
DRUGfirst-line scheme+compound kushen injection
FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab+compound kushen injection Compound Kushen injection: intravenous infusion, 20ml at a time, diluted with 200ml sodium chloride injection, once a day, each cycle of chemotherapy should reach the cumulative dose of 200ml.
DRUGpalliative care group first-line scheme
FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab
Sponsors
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
① Patients with advanced CRC confirmed by pathology or cytology and receiving first-line therapy;② Aged ≥ 18 years old, male or female;③ ECOG score 0-2 points;④ Expected survival ≥ 3 months;⑤ According to RECIST1.1 criteria, at least one detectable lesion;⑥ Voluntarily join the study, sign informed consent, compliance with good cooperation with follow-up.
Exclusion criteria
* Combined with other malignant primary tumors; * Immunohistochemistry/polymerase chain reaction/second-generation sequencing results suggest MSI-H/dMMR patients; * Patients with recurrence and metastasis within 6 months after radical tumor surgery; * Patients who have previously or are undergoing cancer immunotherapy ; Patients undergoing radiation therapy; * Pregnant or lactating women; women of childbearing age and their spouses can not take effective contraceptive measures during and within 6 months after the end of clinical study; ⑥ Psychiatric patients; ⑦ Patients with severe, uncontrolled organic disease or infection, such as decompensated heart, lung, kidney failure caused by intolerance to chemotherapy; ⑧ Patients who have received clinical trials of small molecule drugs within 28 days or received clinical trials of large molecule drugs within 3 months; ⑨ Patients who are known to be allergic to or intolerant of study drugs.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PFS | The time from randomization to tumor progression or death in patients, whichever came first, assessed up to 24 months | Progression Free Survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| OS | The time from randomization to death from any cause after enrollment, whichever occurs first, assessed up to 24 months | Overall survival |
| 1-year survival rate | The proportion of patients with survival period of more than 1 year accounted for the total patients from the beginning of enrollment treatment | The probability of patients surviving more than 1 year after treatment |
| 1-year PFS rate | The proportion of patients with tumor progression or death from enrollment. | the proportion of the total patients who does not with tumor progression or death within 1 year from enrollment. |
Countries
China
Contacts
Primary Contactjie Li
Outcome results
None listed